Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients
- 28 February 2005
- journal article
- guideline
- Published by Elsevier in Journal of Clinical Virology
- Vol. 32 (2), 122-127
- https://doi.org/10.1016/j.jcv.2004.10.009
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- 95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudineJournal of Hepatology, 2004
- 46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)Journal of Hepatology, 2004
- Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis BJournal of Viral Hepatitis, 2003
- Treatment options for chronic hepatitis B not responding to interferonJournal of Hepatology, 2003
- Hepatitis B e antigen-negative chronic hepatitis BHepatology, 2001
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Quantitation of HBV DNA in Human Serum Using a Branched DNA (bDNA) Signal Amplification AssayAmerican Journal of Clinical Pathology, 1995
- Natural History and Control of Perinatally Acquired Hepatitis B Virus InfectionDigestive Diseases, 1992
- Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infectionGastroenterology, 1987
- Chronic hepatitis in HBsAg carriers with serum HBV-DNA and Anti-HBeGastroenterology, 1986